Expanded Natural Killer (NK) Cells for Multiple Myeloma Study
Condition(s):Multiple MyelomaLast Updated:April 4, 2023Completed
Hide Studies Not Open or Pending
Condition(s):Multiple MyelomaLast Updated:April 4, 2023Completed
Condition(s):Refractory Acute Myeloid Leukemia; Relapsed Acute Myeloid LeukemiaLast Updated:April 4, 2023Withdrawn
Condition(s):Non-Hodgkin Lymphoma; Chronic Lymphocytic LeukemiaLast Updated:February 6, 2018Completed
Condition(s):Recurrent Gliosarcoma; Recurrent Supratentorial Glioblastoma; Supratentorial GliosarcomaLast Updated:March 5, 2024Recruiting
Condition(s):Astrocytoma, Grade IV; Giant Cell Glioblastoma; Glioblastoma Multiforme; Cyclophosphamide; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Antiviral Agents; Anti-infective Agents; Analgesics, Non-narcotic; Analgesics; Sensory System Agents; Peripheral Nervous System AgentsLast Updated:August 10, 2022Terminated
Condition(s):Acute Myeloid LeukemiaLast Updated:April 19, 2022Recruiting
Condition(s):CholangiocarcinomaLast Updated:August 1, 2017Active, not recruiting
Condition(s):Colorectal CancerLast Updated:April 17, 2015Completed
Condition(s):Multiple MyelomaLast Updated:May 19, 2017Completed
Condition(s):PD-1 Antibody; DC-Cell; NK-Cell; Gastrointestinal TumoursLast Updated:July 18, 2022Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.